Lung cancers are heterogeneous with respect to histology and molecular abnormalities. Molecular changes should be established prior to institution of therapy. New immunotherapeutic agents are being evaluated in lung cancer. PARP inhibitors may play a role in combination with chemotherapy and/or radiotherapy. The session will provide new information on these novel therapeutic approaches. At the conclusion of this activity, the learner will be able to do the following: 1. Outline a correct histologic and molecular diagnosis. 2. Justify the appropriate treatment based on histology and molecular features. 3. Discuss and treat the side effects associated with appropriate treatment.